The S&P/ASX 200 Health Care Index (ASX: XHJ) has fallen almost 17% year to date. 

However, there are opportunities to find value for investors. 

Let's look at three ASX healthcare shares drawing positive outlooks from experts. 

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. 

This process treats cancerous or diseased cells, an alternative approach to many cancer therapies, which also attack healthy tissue at the same time.

Telix shares have rebounded over the past couple of months, rising 55% since mid February. 

Telix shares rose in March largely because several value-driving catalysts hit at once, improving both fundamentals and investor sentiment.

However, they remain down 48% over the last year. 

In good news for investors, brokers are expecting Telix shares to recover even further. 

Recently, Bell Potter retained its buy rating and $19 price target on this radiopharmaceuticals company's shares. 

From yesterday's closing price of $13.64, this indicates a further upside of roughly 39%. 

Mayne Pharma Group Ltd (ASX: MYX)

Mayne Pharma Group is another ASX healthcare stock that is down significantly from yearly highs. 

It has fallen 32% year to date. 

This includes a 6% decline yesterday, as investors may have reacted negatively to fresh tariff worries.

However, the company is confident the new tariffs will have "no material impact" on its FY27 earnings profile.

The stock price closed yesterday at $2.16, and after the recent fall, it may be another value play.

Two analysts' forecasts via TradingView have an average one-year price target of $5.75 on the stock, indicating more than 160% upside. 

EBR Systems Inc (ASX: EBR)

EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. 

The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.

It is down roughly 30% year to date. However, it is also drawing positive ratings from brokers. 

Yesterday, the company released a preliminary version of its operating metrics. 

The report showed strong Q1 2026 growth in commercial cases.

This prompted Bell Potter to release updated guidance on this ASX healthcare stock along with a price target of $2, indicating a potential 194% rise. 

The post Where is the value amongst ASX healthcare shares? appeared first on The Motley Fool Australia.

New trade war front

US President Donald Trump last week announced that the US would impose tariffs of up to 100% on imported drugs, however, there were carve-outs for companies that had plans to move manufacturing to the US.

There were also tariff caps on certain countries with trade deals with the US, including Japan, South Korea, Switzerland, and the European Union.

CSL said in a statement to the ASX on Tuesday that it had taken note of the new tariff announcement, but said that it was not anticipating a large impact.

The company said:

CSL is working through the details of the Proclamation, but the initial view is that most of CSL's U.S. product sales will not be subject to tariffs. CSL is pleased the U.S. Administration has recognised the unique nature of plasma-derived therapies under the Proclamation. This is consistent with the longstanding approach of special policy accommodations to ensure patient access to these life-saving therapies. CSL's U.S. plasma therapies are derived entirely from U.S. sourced plasma. CSL continues to invest in manufacturing and job creation in the U.S., recently announcing plans to spend $1.5 billion to expand its plasma therapy manufacturing capabilities in Illinois.

CSL said the primary product sold by its Seqirus division in the US was Fluad, which was made in the United Kingdom, where the tariff is currently 10%, with expectations that it would be reduced to zero.

Mayne also in the clear

Relative minnow Mayne Pharma Ltd (ASX: MYX) also said the new tariffs were expected to have "no material impact" on the company's FY27 earnings profile.

Mayne Pharma said there was no tariff to be applied to generic medicines, and there would only be a minimal tariff applied to its women's health portfolio.

It also manufactures branded dermatology products in the US, and hence no tariff would apply.

The company said:

For the Company's Women's Health segment, Mayne Pharma believes the tariffs would not apply to the contraceptives in the branded portfolio and would not have a material effect on the menopause products as only one active pharmaceutical ingredient (API) is sourced internationally, and that API is sourced from a territory under an existing trade deal with the US and subject to a lower tariff.

CSL shares were 2.1% higher in early trade at $141.94, while Mayne shares were 2.6% higher at $2.39.

The post What's the impact of US tariffs on Aussie drugmakers CSL and Mayne Pharma? appeared first on The Motley Fool Australia.

What did Mayne Pharma announce?

For the period from July to November, Mayne reported net revenue of $165 million, down 5.5% on the prior corresponding period, while underlying EBITDA fell to $11.5 million, roughly half the level recorded a year earlier. Management attributed the decline to increased operating costs, higher marketing spend, and the absence of one-off benefits that supported last year's result.

Despite the softer earnings outcome, the update points to solid underlying demand, particularly in the company's Women's Health portfolio. Prescription volumes continued to grow across key brands, with total trade unit volumes up 15% year on year.

Management said additional investment in sales and marketing in both the United States and Australia was deliberately accelerated to build momentum and maximise the long-term value of its intellectual property, even though this weighed on short-term profitability.

The Dermatology division delivered a mixed performance. Revenue declined due to pricing pressure and increased competition affecting older products; however, gross margins improved materially, supported by a greater contribution from newer, branded treatments acquired earlier in the year. This shift in product mix lifted margins to 64% year to date, up from 52% previously.

International operations also recorded a lower contribution as investment increased following the recent PBS listing of NEXTSTELLIS® in Australia. While revenue was broadly flat, margins improved, reinforcing management's view that the current earnings pressure reflects growth investments rather than a deterioration in underlying demand.

Mayne ended November with cash and marketable securities of $83 million, following payments related to recent product acquisitions, legal costs associated with the failed Cosette takeover, and the completion of divestment-related obligations. The company said its cash usage follows a predictable quarterly cycle and remains sufficient to support the current strategy.

What comes next?

Looking ahead, management expects continued volume growth across Women's Health and International segments, with Dermatology benefiting from a full six months of contribution from newer products in the second half of FY26.

The update signals a clear pivot away from corporate activity and toward execution, with the near-term focus on converting growing demand into sustainable earnings recovery.

Mayne Pharma shares were relatively muted following the update and were down 0.8% at the time of writing.

The post Mayne Pharma signals short-term pain as it resets for growth appeared first on The Motley Fool Australia.

US company Cosette Pharmaceuticals Inc launched a $7.40 per share takeover bid for Mayne in February, with the offer a 37% premium to the Mayne share price at the time.

Cosette's doubt emerge

But Cosette later tried to back out of the deal, arguing that there were a number of factors that constituted a "material adverse change" with regard to Mayne's business, including a trading update in April and certain correspondence with the US Food & Drug Administration (FDA).

Mayne, at the time, denied that the arguments put forward by Cosette constituted a material adverse change as defined in the scheme implementation deed for the deal and stated that the company would challenge Cosette's right to withdraw.

As Mayne Pharma said in a statement to the ASX in May:

Mayne Pharma maintains its position that all information relevant to the financial position of Mayne Pharma has been disclosed to the market in the earnings announcement released on 22 April and that there is now new information required to be disclosed in light of the contents of the Cosette notice.

Mayne took the matter to court, winning a ruling in the New South Wales Supreme Court, which denied Cosette's bid to back out of the deal.

Plant closure plans doomed the bid

But the proposed transaction also had a political element, with Cosette's plans to close Mayne's Adelaide-based drug manufacturing plant piquing the interest of the Foreign Investment Review Board and Treasurer Jim Chalmers.

The Treasurer wrote to Cosette in October, saying his "preliminary view is that the proposed acquisition would be contrary to the national interest, on the grounds that it would negatively impact the Australian economy and community''.

That preliminary notice was followed by a formal notification in November that the Treasurer had objected to the proposed takeover.

Mayne said at the time:

As a result, Mayne Pharma is disappointed to inform shareholders that the FIRB condition precedent to the scheme will not be satisfied such that the scheme is unlikely to proceed.

Late on Wednesday this week, Mayne said in a statement to the ASX that it "has not been able to reach any position with Cosette that might allow the scheme to proceed''.

Mayne said it had issued a notice to Cosette "in relation to Cosette's material breaches of the scheme implementation deed with Mayne Pharma considers were wilful and intentional''.

Mayne said it now had the right to terminate the scheme "if the relevant circumstances set out in the notice of intention to terminate continue to exist for five business days, being to 10 December''.

Mayne shares traded as high as $7.31 when the takeover was first announced, but are now changing hands for just $3.36, not far off their 12-month lows of $3.27.

The post Doomed takeover bid for Mayne Pharma to come to an end appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Accent Group Ltd (ASX: AX1)

The Accent share price is down a further 6% to 96 cents. This footwear retailer's shares have been under significant pressure since the release of guidance for FY 2026 at the end of last week. Accent revealed that it expects first half earnings before interest and tax (EBIT) in the range of $55 million to $60 million. This is down sharply from $80.7 million in the first half of FY 2025. For the full year, EBIT in the range of $85 million to $95 million is expected. This will be down from $110.2 million in FY 2025. This has been driven by like for like sales weakness and margin pressure due to promotional activity.

Electro Optic Systems Holdings Ltd (ASX: EOS)

The EOS share price is down over 2% to $4.48. This may have been driven by optimism that Russia and the Ukraine could soon sign a peace deal. While this would be great news for the world, it could reduce near term demand for drone and counter drone technology. EOS has reported very strong sales growth so far this year.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is down a further 18% to $3.65. Investors have been selling this pharmaceutical company's shares since the Foreign Investment Review Board blocked its takeover by Cosette Pharmaceuticals. It said: "Mayne Pharma was notified by Cosette shortly after market open this morning that it had received written notice from the Foreign Investment Review Board (FIRB) stating that the Treasurer has objected to the proposed Scheme. As a result, Mayne Pharma is disappointed to inform shareholders that the FIRB condition precedent to the Scheme will not be satisfied such that the Scheme is unlikely to proceed." The company is now assessing its options and next steps and will keep the market informed as appropriate.

Pilbara Minerals Ltd (ASX: PLS)

The Pilbara Minerals share price is down 2.5% to $3.80. This is despite there being no news out of the lithium miner on Monday. Though, it is worth noting that most ASX lithium stocks are trading lower today. This follows a relatively poor night of trade for their US listed peers on Wall Street on Friday. The Sociedad Química y Minera de Chile (NYSE: SQM) share price fell 2% despite the market rebound.

The post Why Accent Group, EOS, Mayne Pharma, and Pilbara Minerals shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Alliance Aviation Services Ltd (ASX: AQZ)

The Alliance Aviation Services share price is down 7% to $1.35. This appears to have been driven by a couple of broker notes out of Morgans and Ord Minnett. Both brokers have downgraded this aviation services company's shares to a hold rating from buy this morning. Morgans said: "AQZ has released a disappointing trading update with FY26 NPBT expected to be ~40% below our previous forecast and consensus. The stock is now in a very tough spot – ex-growth and earnings going backwards, management changes, accounting issues, highly levered balance sheet, poor cashflow generation and deteriorating returns on capital. With AQZ's strategic review ongoing, we are hopeful of possible corporate activity (but not guaranteed). Despite the poor earnings performance, the stock continues to trade well below NTA of ~A$2.90 and aviation assets are liquid and remain in strong demand. We downgrade our rating to HOLD."

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down almost 7% to 18.2 cents. This morning, this struggling semiconductor company announced a fully underwritten $35 million placement to professional and sophisticated investors. These funds are being raised at a 10.3% discount of 17.5 cents per new share. Brainchip's CEO, Sean Hehir, said: "This capital raise positions BrainChip to accelerate our leadership in edge AI and neuromorphic computing. With Akida 2.0 and our expanding product portfolio, we are unlocking new commercial opportunities in high-growth sectors and driving scalable innovation. Investor support enables us to execute with confidence and deliver long-term value through transformative, on-device intelligence."

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is down almost 4% to $4.72. This has been driven by news that the pharmaceutical company has received a notice of intention to appeal by Cosette Pharmaceuticals. This relates to last month's judgement in the Supreme Court of New South Wales, which found in favour of Mayne Pharma and dismissed Cosette's request to cancel its takeover offer. Mayne Pharma notes that the notice of intention does not include any reasons for Cosette's intention to appeal.

Perpetual Credit Income Trust (ASX: PCI)

The Perpetual Credit Income Trust share price is down over 6% to $1.13. This has been driven by news that the income trust intends to raise up to ~$267 million via a 1 for 2 pro-rata non-renounceable entitlement offer to eligible unitholders and a shortfall offer. The proceeds are intended to be used to enable the investment manager to actively pursue additional investments in accordance with its current investment strategy and objective.

The post Why Alliance Aviation, Brainchip, Mayne Pharma, and Perpetual Credit shares are sinking today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Aeris Resources Ltd (ASX: AIS)

The Aeris Resources share price is down over 12% to 45.5 cents. This morning, this copper miner announced that has received firm commitments to raise $80 million via an institutional placement. These funds are being raised at a discount of 45 cents per share. Commenting on the capital raising, Aeris' executive chair, Andre Labuschagne, said: "This inbound-led placement received strong support from high-quality institutional investors, both in Australia and offshore. The capital raise allows us to deleverage our balance sheet and accelerate exploration and growth initiatives across the group."

Humm Group Ltd (ASX: HUM)

The Humm Group share price is down 12% to 58.5 cents. This follows the release of the lender's quarterly update. Humm revealed that new loan origination volumes were down 14% to $845 million during the quarter. This was driven by double-digit declines in both commercial and consumer volumes. Management advised that this reflects subdued demand, increased competitive pricing pressure, and a strategic decision to originate higher credit quality assets.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is down 32% to $4.19. This has been driven by news that the pharmaceuticals company's proposed takeover could be on the brink of collapsing. This follows a letter from the Foreign Investment Review Board (FIRB). It advised that its "preliminary view is that the Proposed Acquisition would be contrary to the national interest, on the grounds that it would negatively impact the Australian economy and community." Mayne Pharma notes that the letter also states that the Treasurer is considering whether he should make orders prohibiting the acquisition.

Steadfast Group Ltd (ASX: SDF)

The Steadfast share price is down 9.5% to $5.61. This follows news that the insurance broker network operator's CEO is stepping aside following a workplace complaint. It stated: "Robert Kelly AM, the Managing Director & Chief Executive Officer has chosen to stand aside on a temporary basis to enable an external investigation to progress into a workplace complaint made against him." The company has appointed Tim Mathieson, CEO Australasian Broking, to the role of acting CEO, effective immediately.

The post Why Aeris Resources, Humm, Mayne Pharma, and Steadfast shares are sinking today appeared first on The Motley Fool Australia.

US company Cosette Pharmaceuticals Inc launched a $7.40 per share takeover bid for Mayne in February, with the offer a 37% premium to the Mayne share price at the time.

But Cosette later tried to back out of the deal, arguing that there were a number of factors that constituted a "material adverse change" with regards to Mayne's business, including a trading update in April and certain correspondence with the US Food & Drug Administration (FDA).

Mayne denied Cosette's claims and took the matter to court, winning a ruling in the New South Wales Supreme Court recently, which denied Cosette's bid to back out of the deal.

Government could step in

But it has now emerged that Australian Treasurer Jim Chalmers could step in to block the deal on national interest terms.

Mayne told the ASX in a statement today that Mr Chalmers had written to Cosette, indicating that his "preliminary view is that the proposed acquisition would be contrary to the national interest, on the grounds that it would negatively impact the Australian economy and community".  

The statement goes on to say:

The letter states that the Treasurer is considering whether he should make orders prohibiting the acquisition contemplated by the Scheme. Treasury was advised that Cosette had re-evaluated its intentions concerning Mayne Pharma's business in Australia and determined that if Cosette were to acquire Mayne Pharma, its current intention is to seek to dispose of, or close, the manufacturing site in Adelaide.

The letter, Mayne said, went on to say that the Treasurer believed the company's Adelaide site was important to Australia's "pharmaceutical manufacturing and research and development capabilities".

Mayne said it agreed with the Treasurer regarding this view.

Given the valuable nature of the site, Mayne Pharma does not consider that it would be commercially rational to close the site and has consistently communicated this to Cosette since Cosette informed the Foreign Investment Review Board of its stated change of intention on 24 June 2025.

Mayne said the letter from the Treasurer had invited submissions from Cosette about his concerns, and the Australian company said that no final decision had been made by the Treasurer, meaning Cosette was still "obligated … to use its best endeavours to obtain the Treasurer's approval of the scheme''.

Mayne shares fell as low as $3.81 on the news before recovering to be 30.2% lower at $4.33 by mid-morning.

The post All Ords drug maker's shares plunge 30% on takeover troubles appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:

AMP Ltd (ASX: AMP)

The AMP share price is up 10% to $1.94. This follows the release of the financial services company's third quarter update this morning. AMP revealed that its total assets under management (AUM) increased 3.6% quarter on quarter to $159.5 billion. This was driven by its Platforms AUM, which increased 4.5% to $86.9 billion. Management notes that this reflects resilient inflows and positive investment markets. In addition, it revealed that Platforms net cashflows increased by 61.6% over the prior corresponding period to $1.2 billion. AMP's chief executive, Alexis George, said: "In Platforms, the strength of the North proposition continues to be recognised by advisers, with net cashflows up over 60% on pcp and AUM reaching close to $87 billion."

GQG Partners Inc (ASX: GQG)

The GQG Partners share price is up almost 7% to $1.64. This morning, this fund manager announced its next quarterly dividend. GQG Partners intends to pay shareholders the equivalent of 5.6775 cents per share in December. This quarterly dividend equates to an attractive 3.4% dividend yield. Annualised, this would mean dividends of 22.71 cents per share, which is the equivalent of a 13.8% dividend yield.

Jumbo Interactive Ltd (ASX: JIN)

The Jumbo share price is up a further 10% to $11.82. Investors have been bidding this online lottery ticket seller's shares higher this week after it announced a major acquisition. Jumbo is paying $110 million to acquire UK-based Dream Car Giveaways. It is a leading business-to-consumer (B2C) brand and digital market proposition in the UK prize draw market, allowing customers to compete for prizes such as cars, cash, property, and lifestyle products. Commenting on the deal, Jumbo's CEO, Mike Veverka, said: "Jumbo's two decades of B2C success in Australia and its world-class software, marketing, and customer management expertise, provides DCG with the foundation to continue its already impressive growth."

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is up 11% to $6.30. This follows news that the pharmaceuticals company won a court battle against Cosette Pharmaceuticals. The latter has been looking to back out of a takeover deal this year, but the New South Wales Supreme Court has ruled in its favour that no material adverse change had occurred. Mayne Pharma's shares are still trading well short of the $7.40 takeover price, which could be an indication that not everyone is convinced the deal is a foregone conclusion.

The post Why AMP, GQG, Jumbo, and Mayne Pharma shares are racing higher today appeared first on The Motley Fool Australia.

But shareholders in the company could make another 16% on top of that in easy fashion if the takeover goes ahead at the $7.40 offer price, which is expected to happen next month. More on that below.

Extended legal stoush

Mayne Pharma has been tied up in a legal fight with Cosette since May this year, after the US company said it would rescind its takeover offer for the company.

Cosette was arguing that there were a number of factors that constituted a "material adverse change" with regards to Mayne's business, including a trading update in April and certain correspondence with the US Food & Drug Administration (FDA).

Mayne, at the time, denied that the arguments put forward by Cosette constituted a material adverse change as defined in the scheme implementation deed for the deal and said that the company would challenge Cosette's right to back out.

As Mayne Pharma said in a statement to the ASX in May:

Mayne Pharma maintains its position that all information relevant to the financial position of Mayne Pharma has been disclosed to the market in the earnings announcement released on 22 April and that there is now new information required to be disclosed in light of the contents of the Cosette notice.

The Cosette deal, announced to the market in February, offered Mayne shareholders $7.40 per share cash, which at the time was a 37% premium to the prevailing share price.

Despite Cosette's ongoing attempt to back out of the deal, Mayne went ahead with a shareholder vote in June, where the resolution to go ahead with the deal was passed soundly, with 99.06% of shares voted in favour.

Meanwhile, Mayne lodged proceedings in the New South Wales Supreme Court, which this week ruled in favour of Mayne.

As the company said in a statement to the ASX on Thursday:

Mayne Pharma is pleased to announce that in a judgment delivered on 15 October 2025, the Supreme Court of New South Wales found in favour of Mayne Pharma and dismissed Cosette's claims. Mayne Pharma will now take all steps within its power to implement the scheme.

Still value in Mayne shares

The deal still requires approval from the Foreign Investment Review Board, and it also needs to be approved by the Supreme Court at a hearing scheduled for 22 October.

Mayne said, subject to these conditions being met, it was anticipated that the scheme would become effective on 23 October.

Mayne shares jumped sharply on the news, up 12.2% to $6.35; however, they are still well shy of the $7.40 takeover price.

Should shareholders receive that in cash, they'll bank another 16.9% in gains based on Thursday's price mid-morning.

The post Here's a potential double-digit trade gain, following Mayne Pharma's takeover court win appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is down 13% to $4.58. This morning, this pharmaceuticals company released an update on its proposed takeover by Cosette Pharmaceuticals. It highlights that there are reports that the South Australian government would look to block the sale of the business if its suitor were to close its Salisbury operations. Given that Cosette has been looking for ways to get out of the deal, investors appear to believe this could be the nail on the coffin for the takeover. The company said: "Mayne Pharma is aware that, since Cosette's purported termination of the Scheme, Cosette has had some correspondence with FIRB in respect of its intentions for the Mayne Pharma business (including possible intentions to either close or sell the Salisbury site) following implementation of the Scheme, should Cosette's attempts to terminate, or otherwise get out of its obligations under, the SID, fail."

Metal Powder Works Ltd (ASX: MPW)

The Metal Powder Works share price is down over 4% to $3.53. This morning, this advanced metal powder production technology developer announced that it has received firm commitments from sophisticated and professional investors to raise $15 million through a share placement priced at $3.50 per share. Its CEO, John Barnes, said: "The additional A$15 million in funding provides us with the balance sheet strength to accelerate our growth strategy, scale production, grow market share, broaden our product offering while maintaining the financial strength to execute at speed."

Smartgroup Corporation Ltd (ASX: SIQ)

The Smartgroup share price is down 5% to $8.63. This has been driven by the salary packaging and fleet management's company's shares going ex-dividend this morning for its fully franked interim dividend of 19.5 cents per share. This will be paid to eligible shareholders later this month on 23 September.

Super Retail Group Ltd (ASX: SUL)

The Super Retail share price is down 4% to $18.09. This has also been caused by the retail conglomerate's shares going ex-dividend this morning. Last month, the BCF, Macpac, Rebel, and Supercheap Auto owner released its full year results and declared a fully franked final dividend of 34 cents per share and a fully franked special dividend of 30 cents per share. These will be paid to eligible shareholders next month on 16 October.

The post Why Mayne Pharma, Metal Powder Works, Smartgroup, and Super Retail shares are dropping today appeared first on The Motley Fool Australia.

Some invest in safe-haven stocks and assets, while others are willing to take on more risk in the hope of hitting the jackpot.

The Australian recently compiled a list of 10 Australian billionaires, and the stocks they like to invest their money into.

Gina Rinehart

The Australian heiress, billionaire mining magnate, and businesswoman has built a $2 billion stock portfolio through Hancock Prospecting. It consists mainly of mining stocks and exchange-traded funds. The company owns shares in US-listed stocks such as Tesla Inc (NASDAQ: TSLA), Fox Corp (NASDAQ: FOX), and Trump Media & Technology Group Corp (NASDAQ: DJT).

Hancock Prospecting also has exposure in Australian markets. Hancock is a major shareholder in gold producer Ballard Mining Ltd (ASX: BM1), which floated on the ASX on July 14, 2025. 

Gerry Harvey

Australian entrepreneur and executive chairman of Harvey Norman Holdings Ltd (ASX: HVN), Gerry Harvey, backs New-Zealand based Briscoe Group Ltd (ASX: BGP). Briscoe comprises homewares stores and now Rebel Sports outlets. 

Bruce Mathieson

Bruce Mathieson is known for his influence in the Australian pub, hotel, and gambling sectors. 

According to The Australian, Mathieson has some of his fortune locked up in Endeavour Group Ltd (ASX: EDV) shares, shares in Star Entertainment Group Ltd (ASX: SGR), and shares in Mayne Pharma Group Ltd (ASX: MYX). He also has shares in RAS Technology Holdings Ltd (ASX: RHL).

Chris Morris

Chris Morris built share registry services firm Computershare Ltd (ASX: CPU) and maintains a large holding in the business. He also has shares in US data storage company Seagate Technology Holdings PLC (NASDAQ: STX).

James Packer

The Crown Resorts Ltd (ASX: CWN) king sold out of the business in 2022 and has since invested money into US technology stocks. His biggest holdings are in Nvidia Corp (NASDAQ: NVDA), Taiwan Semiconductor Manufacturing Co Ltd (TPE: 2330), Shopify Inc (NASDAQ: SHOP), Spotify Technology SA (NYSE: SPOT), and Monday.Com Ltd (NASDAQ: MNDY).

Alan Rydge

Alan Rudge's wealth is mostly in two ASX-listed companies, which he has led for 45 years – Carlton Investments (ASX: CIN) and EVT Ltd (ASX: EVT). He is also a long-time stockholder of Harvey Norman shares.

Ed Craven

Ed Craven is Australia's youngest billionaire. He is well known for his cryptocurrency gambling empire Stake.com, and Kick streaming. He and his business partner Bijan Tehrani also have a 5% shareholding in Australian bookmaker Pointsbet Holdings Ltd (ASX: PBH).

Bruce Gordon

Bruce Gordon owns the Australian television network WIN Television through his ownership of WIN Corporation, the largest shareholder of Nine Entertainment Co Holdings Ltd (ASX: NEC). He also has shares in Singapore's mobile and telecommunication network Tuas Ltd (ASX: TUA).

Kerry Harmanis

Kerry Harmanis was the founder and executive chairman of Jubilee Mines NL, a highly successful Western Australian nickel miner which he established in 1987. Today, he still dabbles in mining shares, including Talisman Mining Ltd (ASX: TLM) and Centauras Metals Ltd (ASX: CTM).

Mark Creasy

Mark Creasy is one of Australia's most successful prospectors. He has a minority stake in nickel and lithium miner IGO Ltd (ASX: IGO), as well as a handful of other mining stocks. He recently invested into exploration company Lexington Gold Ltd (LON: LEX).

The post Australian billionaires: Which stocks do they own? appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:

Coronado Global Resources Inc (ASX: CRN)

The Coronado Global share price is up almost 40% to 14.5 cents. Investors have been buying this coal miner's shares after it shored up its balance sheet. This morning, Coronado Global revealed that it has entered into a binding commitment for a $150 million asset-based lending facility with Oaktree Capital Management. The company's CFO, Barrie Van der Merwe, commented: "Entering into this transaction with Oaktree is an important first step in our strategy to stabilise and strengthen our financial position. It reflects a clear confidence from a credible lender in the underlying value of our asset base and business fundamentals."

DroneShield Ltd (ASX: DRO)

The DroneShield share price is up a further 9% to $1.53. Investors have been fighting to get hold of the counter drone technology company's shares this week. This appears to have been driven by news that the UK government is planning to spend GBP2 billion (~A$4.2 billion) on drone technology to boost its military capabilities. All this attention on drone warfare from governments around the globe bodes well for DroneShield.

Lovisa Holdings Ltd (ASX: LOV)

The Lovisa share price is up 7.5% to $31.55. This morning, this fashion jewellery retailer announced that its new CEO, David Cheston, has now started. He was previously the CEO of the Smiggle brand, which is owned by Premier Investments Ltd (ASX: PMV). It also revealed that it has appointed Mark McInnes as executive deputy chairman, effective today. Lovisa's chair, Brett Blundy, said: "Mark's extensive experience and proven track record of success in large Australian ASX listed retailers, combined with his leadership skills make him an invaluable member of the Board and Executive Management team. We are confident that his contributions will further strengthen our position in the industry and drive long-term value for Shareholders."

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is up 5% to $4.97. This has been driven by the release of an update on its troubled takeover. The pharmaceuticals company advised that its suitor, Cosette Pharmaceuticals, has not yet terminated the scheme implementation scheme following a 10-business day consultation period. Cosette was looking to cancel the deal, alleging that a material adverse change had occurred. The company adds: "Mayne Pharma has reminded Cosette of its obligations to comply with the SID, including to progress the application for FIRB approval."

The post Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:

ARB Corporation Ltd (ASX: ARB)

The ARB share price is up 2% to $30.80. This may have been driven by a broker note out of Ord Minnett this morning. Its analysts have reaffirmed their buy rating on the 4×4 auto parts company's shares with a trimmed price target of $37.00. While it has lowered its earnings estimates in response to near term challenges, it remains positive and sees plenty of value in its shares at current levels following weakness this year.

Block Inc (ASX: XYZ)

The Block share price is up almost 6% to $90.69. This follows a strong night of trade for the payments giant's shares on Wall Street. One leading broker that would be supportive of this buying is Morgan Stanley. A recent note reveals that its analysts have an overweight rating and US$67 price target on its NYSE-listed shares. This implies potential upside of approximately 15% over the next 12 months.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is up 8% to $4.71. This pharmaceutical company's shares are rebounding on Friday after a brutal selloff this week. Investors have been rushing to the exits since the company revealed that its takeover deal could collapse. This has been driven by the receipt of a notice from Cosette Pharmaceuticals, alleging that a "Material Adverse Change" has occurred. This potentially gives its suitor the right to walk away from the $672 million takeover deal. Cosette cited a combination of issues as the basis for its claim. This includes Mayne Pharma's recent earnings update, ongoing litigation with TXMD, and an FDA letter.

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is up 7% to $5.79. Investors have been buying Paladin Energy and other ASX uranium shares today amid optimism that the industry could get a big boost from US President Donald Trump. According to Reuters, Trump is expected to sign executive orders on Friday that aim to jumpstart the nuclear energy industry. It said: "A draft summary of the orders said Trump will invoke the Cold War-era Defense Production Act to declare a national emergency over U.S. dependence on Russia and China for enriched uranium, nuclear fuel processing and advanced reactor inputs."

The post Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Dexus (ASX: DXS)

The Dexus share price is down 3.5% to $6.98. Investors have been selling the property developer's shares after it released another update on Australia Pacific Airports Corporation (APAC), which is the owner of Melbourne and Launceston Airports. Last week, it advised that it received a notice from the APAC Board alleging that it used a confidentiality deed poll and disclosed confidential information in the Dexus Bloc sale process. This would be in breach of the requirements under the APAC Shareholders' Deed. Today it has obtained an injunction against APAC. However, in exchange, it has committed to pay any damages that may arise in the event that its claim does not succeed.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is down a further 3.5% to $4.39. This pharmaceutical company's shares have been sold off this week amid concerns that its takeover deal could collapse. This has been driven by the receipt of a notice from its suitor, Cosette Pharmaceuticals, alleging that a "Material Adverse Change" has occurred. This potentially gives Cosette the right to walk away from the $672 million deal. Cosette cited a combination of issues as the basis for its claim. This includes Mayne Pharma's recent earnings update, ongoing litigation with TXMD, and an FDA letter.

Nufarm Ltd (ASX: NUF)

The Nufarm share price is down a further 8% to $2.58. Investors have been selling this crop protection company's shares this week following the release of its half year results. Nufarm reported a 3% lift in revenue to $1,811 million but a 39% decline in statutory net profit after tax to $29.8 million. This was driven by its Seed Technologies business, which reported a 71% decline in underlying EBIT to $15.9 million. This reflects lower licensing revenues, lower margins in omega-3, and lower canola revenues in Australia.

Treasury Wine Estates Ltd (ASX: TWE)

The Treasury Wine share price is down 1.5% to $8.42. This may have been driven by a broker note out of Ord Minnett. According to the note, the broker has downgraded the wine giant's shares to a neutral rating with a $9.50 price target. It has concerns over rising headwinds and the announcement of a change of CEO.

The post Why Dexus, Mayne Pharma, Nufarm, and Treasury Wine shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

James Hardie Industries plc (ASX: JHX)

The James Hardie share price is down 7% to $35.79. This follows the release of the building materials company's quarterly update. James Hardie posted a 1% decline in net sales to US$3,877.5 million and a 17% drop in net profit to US$424 million. While this meant that it still achieved its full year guidance, its outlook commentary for FY 2026 may have disappointed. Management warned: "More recent, broader macroeconomic uncertainty could further impact the cost of home construction and weigh on consumer sentiment, influencing demand."

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is down 30% to $4.52. Investors have been selling this pharmaceutical company's shares amid concerns that its takeover deal could collapse. This follows the receipt of a notice from its suitor, Cosette Pharmaceuticals, over the weekend alleging that a "Material Adverse Change" had occurred. This potentially gives Cosette the right to walk away from the $672 million deal. Cosette cited a combination of issues — including Mayne's recent earnings update, ongoing litigation with TXMD, and an FDA letter — as the basis for its claim.

Nufarm Ltd (ASX: NUF)

The Nufarm share price is down over 28% to $2.88. This has been driven by the release of the crop protection company's half year results this morning. Nufarm reported a 3% lift in revenue to $1,811 million but a 39% decline in statutory net profit after tax to $29.8 million. This was driven by its Seed Technologies business, which reported revenue of $249 million and underlying EBIT of $15.9 million. The latter was down 71% decline on the prior corresponding period due to lower licensing revenues, lower margins in omega-3, and lower canola revenues in Australia.

Resimac Group Ltd (ASX: RMC)

The Resimac share price is down 4% to 81.7 cents. This follows news that ASIC has commenced civil penalty proceedings against the non-bank lender. Resimac revealed that the regulator is alleging contraventions in relation to hardship notices under the National Consumer Credit Protection Act. The company responded: "Resimac acknowledges that its previous practices regarding hardship notices provided by customers could have been better and apologises that this has occurred. Since becoming aware of the issue, Resimac has enhanced its processes to give greater support to customers facing financial difficulties."

The post Why James Hardie, Mayne Pharma, Nufarm, and Resimac shares are falling today appeared first on The Motley Fool Australia.

At the time of writing, the ASX 300 share is down by a staggering 33% to $4.31.

As a comparison, the S&P/ASX 200 index is up 0.6% today.

Why is this ASX 300 share taking a tumble?

As some readers may be aware, this pharmaceutical company received and accepted a takeover offer earlier this year from US-based Cosette Pharmaceuticals.

Things have been moving along very nicely. In fact, the Federal Court approved a scheme meeting last week, with shareholders invited to vote on the deal next month.

However, a major development has happened which has sparked fears that Mayne Pharma's $672 million takeover deal could be on the verge of collapse.

What happened?

This morning, Mayne Pharma revealed that it received a notice from Cosette over the weekend alleging that a "Material Adverse Change" had occurred, potentially giving Cosette the right to walk away from the deal.

Cosette cited a combination of issues — including Mayne's recent earnings update, ongoing litigation with TXMD, and an FDA letter — as the basis for its claim.

In response, Mayne Pharma has firmly rejected Cosette's allegations, arguing that no material adverse change has occurred, that all relevant financial information was already disclosed to the market in April, and that Cosette's claims are speculative and unquantified. It said:

The Cosette Notice does not currently quantify the full financial impact of the cumulative matters that Cosette asserts constitute a Mayne Material Adverse Change (being Mayne Pharma's trading performance, including the circumstances associated with the Mayne Pharma 22 April 2025 earnings update, the previously disclosed litigation with TXMD, and certain correspondence with regulators including the FDA Untitled Letter disclosed by Mayne Pharma on 14 May 2025) and in Mayne Pharma's view does not otherwise establish the pre-requisites for a Mayne Material Adverse Change, as defined in the SID.

Is the deal dead?

Not yet — but the next few days will be crucial. Cosette hasn't terminated the deal but has triggered a 10-business-day consultation period. This is a formal process required under the agreement before any termination can occur.

If those discussions fail, Cosette has said it may issue a termination notice.

Mayne Pharma, meanwhile, insists the deal is still binding and says it is pushing ahead with the transaction as planned.

But with the ASX 300 share crashing deep into the red today, it seems that the market believes the deal could be as good as dead. Time will tell if this is the case.

The post This ASX 300 share is sinking 33% on takeover collapse fears appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are jumping:

Domain Holdings Australia Ltd (ASX: DHG)

The Domain share price is up 38% to $4.30. Investors have been fighting to get hold of the property listings company's shares after it received a $2.7 billion takeover offer from CoStar Group, Inc. (NASDAQ: CSGP). CoStar has made a non-binding offer of $4.20 cash per share, which represents a sizeable 34.6% premium to its last close price. The Domain board advised that it has commenced an assessment of CoStar's proposal.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is up 33% to $7.20. This morning, this pharmaceutical company revealed that it has accepted a takeover offer from Cosette Pharmaceuticals. The two parties have agreed a price of $7.40 per share, which represents a 36.8% premium to where the ASX 300 pharma stock last traded. Cosette Pharmaceuticals is a US based pharmaceutical company with a portfolio of products in women's health and dermatology. Management is recommending shareholders vote in favour of the transaction. This is in the absence of a superior offer and subject to the independent expert's report.

QBE Insurance Group Ltd (ASX: QBE)

The QBE share price is up 7.5% to $21.59. Investors have been buying this insurance giant's shares following the release of its full year results. QBE posted a 31.3% year on year increase in statutory net profit after tax to US$1.78 billion. This was driven by gross written premium growth of 3% and a combined operating ratio of 93.1%. In light of this strong result, the QBE board elected to boost its final dividend by 31% to 63 cents per share.

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix Pharmaceuticals share price is up 14% to $30.18. This has been driven by the release of the pharmaceutical company's full year results following the market close on Thursday. Telix posted an impressive 56% increase in revenue to $783.2 million and a whopping 860% jump in profit after tax of $49.9 million. More strong growth is expected in FY 2025. Management is guiding to revenue of $1.18 billion to $1.23 billion for the year. This represents an increase of approximately 51% to 57%, respectively, year on year.

The post Why Domain, Mayne Pharma, QBE, and Telix shares are jumping today appeared first on The Motley Fool Australia.

In morning trade, the ASX 300 healthcare stock is up 34% to $7.25.

Why is this ASX 300 healthcare stock rocketing?

Investors have been scrambling to buy the company's shares this morning after it revealed that it has accepted a takeover offer.

According to the release, the company has entered into a scheme implementation deed with Cosette Pharmaceuticals that will see the latter acquire 100% of the shares in Mayne Pharma by way of a scheme of arrangement.

The two parties have agreed a price of $7.40 per share, which represents a 36.8% premium to where the ASX 300 healthcare stock last traded.

Cosette Pharmaceuticals is a US based pharmaceutical company with a portfolio of products in women's health and dermatology.

The company highlights that it has a history in the manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions, and suppositories. It has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by 350 plus team members across all functional areas.

The release notes that Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane (NASDAQ: HLNE)., a private markets investment management firm.

Unanimously recommended

The Mayne Pharma board advised that it unanimously recommends that shareholders vote in favour of the scheme. This is in the absence of a superior proposal and subject to the independent expert's report.

The company's two largest shareholders, Viburnum Funds and Bruce Mathieson, who collectively own a 14.1% stake, intend to vote in favour of the scheme.

'A pivotal moment'

The ASX 300 healthcare stock's chair, Frank Condella, was pleased with the deal. He said:

We are pleased that Cosette has recognised significant value in Mayne Pharma, particularly in our women's health and dermatology businesses, and the offer provides shareholders with the opportunity to receive cash value at a significant premium. The Board believes that the proposed transaction is in line with the Board's priority to deliver value to our shareholders, and also provides significant benefits for our broader stakeholders.

This sentiment was echoed by the company's CEO, Shawn Patrick O'Brien. He said:

Today marks a pivotal moment in Mayne's journey to improve patient access to life-enhancing medications. Attracting an offer from a strategic buyer who is active in the US Dermatology and Women's Health markets, such as Cosette, reflects the excellent work our teams have been doing to strengthen our company over the last year and more.

Having broadened our portfolio in Dermatology and Women's Health, and improved patient access through a refined US channel strategy, we have executed against our corporate strategies with precision. As we enter this new chapter, we do so as a stronger, more agile company.

The post Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news appeared first on The Motley Fool Australia.

Shares in the Aussie pharmaceuticals company closed on Friday trading for $4.68. During the Monday lunch hour, shares are swapping hands for $5.60 apiece, up 19.7%.

That's enough to lift the Mayne Pharma share price's one-year performance back into the green, up 3.8% over 12 months.

Here's what spurring buying interest in the ASX 300 healthcare stock today.

ASX 300 healthcare stock rockets on strong growth

The Mayne Pharma share price is going ballistic after the company released its preliminary half-year results for the six months ending 31 December.

The company announced that it expected its H1 FY 2025 revenue to be between $210 million and $215 million. This represents a 12% to 14% year-on-year revenue increase.

On the earnings front, Mayne Pharma said it expected to report 1H FY 2025 underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of $30 million to $32 million. This is up a whopping 275% to 300% from the company's H1 FY 2024 earnings.

The company credited the strong half-year earnings boost to continued growth across its Women's Health portfolio with increased operating leverage. The ASX 300 healthcare stock said its Dermatology unit also saw an improvement in margin, primarily through its product mix.

What did management say?

Commenting on the strong half year for the ASX 300 healthcare stock, Mayne Pharma CEO Shawn Patrick O'Brien said:

We have experienced solid trading conditions in the first half as we execute against our corporate strategies, with robust revenue growth recorded particularly within our Women's Health segment.

We look forward to further updating our investors on our progress and plans at the half year results presentation in late February.

Mayne Pharma is scheduled to release its audited half-year financial results on 26 February.

Management noted that Mayne Pharma's performance since the update provided at its annual general meeting (AGM) on 21 November should be reflected across the entire half and not assumed as a two-month run rate going forward.

As for what investors might expect from the ASX 300 healthcare stock in the second half of FY 2025? The company said it expected to see continued growth, with some seasonal cost impacts from patient payment programs as deductibles reset, along with an increase in promotional expenses for its Women's Health products to drive additional growth.

The post Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth appeared first on The Motley Fool Australia.